The Case for Statins: Has it Really been Made?

http://nf4.newsfutures.com/bk/market/grpIndex.html?_gid=14. Accessed 2 May, 2004

Lewis J.A. , Jonsson B. , Kreutz G. , Sampaio C. , van Zwieten-Boot B. Placebo-controlled trials and the Declaration of Helsinki. Lancet 2002; 359: 1337–40

European Atherosclerosis Society. Strategies for the prevention of coronary heart disease: a policy statement. Eur Heart J 1987; 8: 77–88

The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988; 148: 36–69

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57

Sacks F.M. , Pfeffer M.A. , Moye L.A. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–9

Lewis S.J. , Moye L.A. , Sacks F.M. . Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998; 129: 681–9

Shepherd J. , Gobbe S.M. , Ford I. . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–7

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized in pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998–3007

Downs J.R. , Clearfield M. , Weis S. . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/ Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–22

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22

Collins R. , Armitage J. , Parish S. , Sleigh P. , Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005–16

Freemantle N. , Calvert M. , Wood J. , Eastaugh J. , Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003; 289: 2554–9

Thompson A. , Temple N. Ethics, Medical Research, and Medicine. Dordrecht: Kluwer Academic Press, 2001

Thompson A. , Temple N. , eds. Ethics, Medical Research, and Medicine: Commercialism Versus Environmentalism and Social Justice. London: Kluwer Academic, 2001

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–421

Fedder D.O. , Koro C.E. , L'Italien G.J. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002; 105: 152–6

Marshall T. Coronary heart disease prevention: insights from modelling incremental cost effectiveness. BMJ 2003; 327: 1264–7